Company Profile
Kiora Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- KPRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.56 USD (+0.79%)
Close
Last updated: August 6, 2026
12.1M USD
Market cap
Why the stock is moving
The latest monitored company update is “Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update.” The corresponding closing-price reaction is not yet available.
Company overview
Retinal-Disease Pipeline
Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches.
KIO-301
KIO-301 is a light-sensitive small molecule intended to restore visual signaling in patients with inherited retinal degeneration by conferring light responsiveness on surviving retinal cells. It is being evaluated in the Phase 2 ABACUS-2 study.
Additional Ophthalmic Program
Kiora's pipeline also includes a second clinical retinal program supported through collaboration funding, giving the company multiple opportunities to test its small-molecule approach in serious eye disease.
Future catalysts
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline. The update that sharpened the story was First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodate the strong.... That is the part of the story investors will probably keep circling back to.
Recent news
- 01
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Source: Kiora Pharmaceuticals
- 02
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Source: Kiora Pharmaceuticals
- 03
- 04
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Kiora Pharmaceuticals
- 05
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Source: Kiora Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kiora Pharmaceuticals (KPRX)?
Kiora Pharmaceuticals (KPRX) most recently closed at 2.56 USD, a +0.79% move versus the previous session.
What is the market cap of Kiora Pharmaceuticals (KPRX)?
Kiora Pharmaceuticals currently has a market capitalization of 12.1M USD on BioPharmSignal.
What does Kiora Pharmaceuticals do?
Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches. KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in patients with...
On which exchange is KPRX stock listed?
Kiora Pharmaceuticals (KPRX) is associated with NASDAQ, United States, Biopharma.
What is KIO-301?
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline.
Which conditions is Kiora Pharmaceuticals targeting with KIO-301?
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline.
How does Kiora Pharmaceuticals describe recent progress with KIO-301?
The main thing to watch at Kiora Pharmaceuticals is ABACUS-2, KIO-301, and the rest of its current pipeline.
What is ABACUS-2?
It is being evaluated in the Phase 2 ABACUS-2 study.